TargetBeta
IL36R
interleukin 36 receptor · also IL1R-rp2, IL1RRP2, IL-36R, IL1RL2 · Immunoglobulin like domain containing
2 programs in company-led studies act on IL36R, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| SHR-1139 | Jiangsu HengRui Medicine | phase 2 | 87 running | IL23A | the company's pipeline |
| TQH2929 | Sino Biopharmaceutical | phase 2 | 31 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Psoriasis, 2 programs
- Colitis, Ulcerative, 1 program
- Pyoderma Gangrenosum, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026SHR-1139 · Jiangsu HengRui Medicine · phase 2 · NCT07719530
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.